German pharma companies are meeting the corona "stress test"
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.
Amidst the coronavirus pandemic people in many countries worry whether too many crucial elements in their healthcare systems have been outsourced, in particular to China. In an interview with Germany Trade & Invest, Han Steutel, the president of the German Association of Research-Based Pharmaceutical Companies (VfA), has said he believes that's not a concern for German pharma.
"Germany is one of the world's strongest production locations where innovative, patented medications are concerned," Steutel explained. "Even amidst the stress test of the corona pandemic, Germany has remained capable of delivering and has exported significantly more patented medical products to China than it has imported from that country."
Death rates from Sars-CoV-2, the respiratory disease caused by the coronavirus, are far lower in Germany than almost everywhere else in the world. The VfA says German expertise is hard at work in all areas of the fight against corona-related ailments.
"There are around 60 companies and institutes working at top speed on vaccines," said Steutel. "Several dozens of existing medications are being tested to see if they can help corona patients. And a series of new medications are being developed, mostly on the basis of antibodies. German companies and institutes are part of all three efforts."
Steutel added that Germany's 44 researched-based pharmaceutical companies were cooperating internationally and with biotech firms in the search for corona medications.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.